Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL...
Saved in:
Main Author: | Vijay, Varsheni |
---|---|
Other Authors: | Li Yinghui |
Format: | Student Research Poster |
Language: | English |
Published: |
Nanyang Technological University
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/170727 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL
by: Lim, Shen Kiat, et al.
Published: (2023) -
Treatment outcomes and clinical relevance in patients with double expressor DLBCL
by: Sirapat Rungwittayatiwat, et al.
Published: (2022) -
Contribution of metabolic reprogramming to genome instability in cancer progression
by: Woo, Ren He
Published: (2015) -
Identification of molecular factors mediating therapeutic resistance in diffuse large B-cell lymphoma (DLBCL)
by: Peng, Chenchen
Published: (2024) -
High-throughput RNA sequencing transcriptome analysis of ABC-DLBCL reveals several tumor evasion strategies
by: Serrano López J.
Published: (2023)